On December 28, Becton, Dickinson and Company (BDX), or BD, received clearance for its Bard (BCR) acquisition form MOFCOM (Ministry of Commerce of the People’s Republic of China), but the approval is contingent on the divestment of BD’s soft tissue core needle biopsy product line.
The S&P 500 Dividend Aristocrat Index is made up of 51 S&P 500 (SPY) (SPX-INDEX) companies that have increased their dividends for 25 successive years.
Stock performance Varian Medical Systems (VAR) closed at $96.20 on August 9, 2017. It has a 50-day moving average of $102.30, and a 200-day moving average of $93.20. On August 9, 2017, Varian stock was trading ~27% above its 52-week low of $75.90 on November 9, 2016, and ~10% below its 52-week high of $107.10 on […]
Company guidance Year-over-year, Varian Medical Systems (VAR) expects its 4Q17 revenue to be flat or fall. According to the company, headwinds from the euro, British pound, and Japanese yen are expected to have an impact of around $10 million, $12 million, and $15 million, respectively. The company’s diluted EPS (earnings per share) are expected to be […]
Varian Medical Systems’ long-term goals Varian Medical Systems (VAR) hopes to improve the lives of around 6 million cancer patients each year, which would double what the company has achieved to date. Varian is aiming for 5%–6% annual revenue growth, whereas its current 12-month trailing revenue growth is 3%. Varian aims to achieve a 22% return […]
Wall Street analysts estimate that Baxter International’s 2Q17 revenues should come in at ~$2.6 billion, a rise of ~0.4% on a year-over-year basis. The company reported revenues of $2.5 billion in 1Q17.
On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.
On April 23, 2017, Becton, Dickinson and Company (or BD) (BDX) announced it will acquire C.R. Bard (BCR) for $317 per Bard share, for a $24.0 billion cash and stock deal.
Revenue estimates On October 25, 2016, Baxter International (BAX) will announce its fiscal 3Q16 earnings for the period ending September 30, 2016. Wall Street has estimated Baxter’s 3Q16 revenue to be about $2.55 billion, a marginal decline from last quarter’s revenue of ~$2.58 billion. Investors can gain exposure to Baxter by investing in the iShares Edge […]
C.R. Bard (BCR) reported ~$931.5 million in total revenues in 2Q16. Of that, ~$255.3 million was contributed by the company’s Vascular business segment.
On July 26, 2016, C.R. Bard (BCR) released its 2Q16 earnings. After the announcement, BCR’s share price rose by ~1%, driven by its better-than-expected 2Q16 results.
Baxter International’s adjusted operating margin came in at ~12.3% in 2Q16, driven by strategic business alignment, portfolio optimization, and cost containment measures.
Varian Medical Systems (VAR) is a global medical device company that generates ~50% of its total revenues from North America and 26% and 24% of total revenues from Europe and Asia, respectively.
Varian Medical Systems has ventured into the proton therapy business and has a huge product pipeline in this area. The company generated approximately $300 million through its proton therapy business in 2015.
Varian Medical Systems’ next big technology innovation will be high-definition radiotherapy, which is an intelligent treatment delivery system that aims to achieve 100% radiation exposure for the tumor.
Varian Medical Systems’ Imaging Components segment accounts for approximately 19% of the company’s total revenue. The segment reported a revenue decline of ~10% in 2015.
Varian Medical Systems (VAR), headquartered in Palo Alto, California, is a leading radiation oncology treatment device and software manufacturer. It reported revenues of approximately $3.1 billion in 2015.
In recent years, Boston Scientific (BSX) has grown significantly through expansion of its product portfolio and geographic reach, as well as the reorganization and cost containment measures.
Based on recommendations of 16 surveyed broker firms, 19% of them gave Baxter a consensus rating of “buy.” The company was rated “hold” by 81% of the analysts. None of the firms rated Baxter a “sell.”
Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$898 million, or ~38%, came from Baxter’s Renal Products business.
Baxter International (BAX) revised its 2016 guidance as the company reported a strong 1Q16. Sales guidance for the year is updated from the 2%–3% range to approximately 3%.
Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$1.5 billion was contributed by the company’s Hospital Products business.
On April 26, 2016, Baxter International (BAX) released its 1Q16 earnings. After the announcement, Baxter’s share price rose ~1% from $43.63 on April 25, 2016, due to the company’s better-than-expected 1Q16 results.
Baxter witnessed a series of changes in 2015, including a change in management, operational structure, and the establishment of a new strategic framework.
The US Food and Drug Administration’s Center for Devices for Radiological Health (or USFDA/CDRH) regulates the medical device industry in the United States.
ValueAct Capital (VAC) is a San Francisco–based investment company that manages more than $12 billion on behalf of several institutional and individual investors. Why sell Techne Corp. (TECH)?
ValueAct Capital (VAC) is a San Francisco–based investment company that manages more than $12 billion on behalf of several institutional and individual investors. Why sell C.R. Bard Inc. (BCR)?
ValueAct Capital (VAC) is a San Francisco–based investment company that manages more than $12 billion on behalf of several institutional and individual investors. Why buy Valero Energy Corp. (VLO)?
ValueAct Capital (VAC) is a San Francisco–based investment company that manages more than $12 billion on behalf of several institutional and individual investors. Why buy Allison Transmission Holdings (ALSN)?
